Abstract: An anti-Epidermal Growth Factor Receptor (EGFR) and anti-Cluster-of-Differentiation (CD3) bispecific antibody and uses thereof are provided. The bispecific antibody can specifically bind to antigen epidermal growth factor receptor (EGFR) on tumor cell surface and antigen CD3 molecule on immune cell surface. The single-chain antibody (ScFv) of an anti-CD3 antibody is located at the C terminal of the constant region of the anti-EGFR antibody. Further provided are a preparation method of the bispecific antibody and clinical applications of the bispecific antibody. The bispecific antibody has high affinity, and is used for treating tumor diseases caused by high expression or abnormal expression of the EGFR and other diseases caused by other overexpression of the EGFR.

Abstract: The application discloses an anti-Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) monoclonal antibody, an amino acid sequence comprising coded antibody variable regions and Complementarity-Determining Regions (CDR), the obtaining method, and application of monoclonal antibody. The anti-PCSK9 monoclonal antibodies are screened from a phage antibody library; affinity maturation is achieved by using a method that the phage antibody library is established by means of chain displacement; After screening the light chain CDR1, 2, 3 Mutant Library of monoclonal antibodies obtained from primary screening; monoclonal antibodies having high affinity are selected; then screening the mutant libraries of heavy chain CDR1, 2, 3 regions; and finally the monoclonal antibodies having high affinity are screened.

Abstract: The application belongs to the technical field of biomedicines and provides an improved anti-Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) monoclonal antibody and an application thereof. By a computer-aided simulation design, a novel phage antibody library is designed, and an improved anti-VEGFR-2 monoclonal antibody is obtained after multiple rounds of screening. Both affinity and biological activity of the antibody are higher than those of an original antibody. The antibody is capable of effectively inhibiting combination of VEGFR-2 and a ligand Vascular Endothelial Growth Factor (VEGF) thereof in vitro, and may be used in treating a tumor and a disease caused by angiogenesis such as macular degeneration.

Abstract: The invention provides human monoclonal antibodies that specifically bind to PD-1 with high affinity. The anti-PD-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed. The synthetic antibody libraries used to select for the high affinity anti-PD-1 monoclonal antibodies were made by replacing the light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR 2 and CDR 3 of phage libraries from the preliminary screening, and the high affinity anti-PD-1 monoclonal antibodies were selected. The human anti-PD-1 monoclonal antibodies have high affinity and inhibit the binding of PD-1 to its ligand PD-L1. The antibodies can be used for treating tumor, inflammation and autoimmune diseases.

Abstract: Provided are a fusion protein of Exendin-4 and its analog, the preparation method and use thereof. The fusion protein is obtained by fusing of Exendin-4 or its analog to Fc region of human IgG2 via a linking peptide, which has the better stability and prolonged serum half-life, and can be used for treating diabetes and obesity.

Abstract: Provided are a fusion protein of Exendin-4 and its analog, the preparation method and use thereof. The fusion protein is obtained by fusing of Exendin-4 or its analog to Fc region of human IgG2 via a linking peptide, which has the better stability and prolonged serum half-life, and can be used for treating diabetes and obesity.